Department of Dermatology, Northwest Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Department of Hematology, Northwest Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Arch Dermatol Res. 2013 Jan;305(1):35-47. doi: 10.1007/s00403-012-1260-2. Epub 2012 Jun 28.
Increasing evidences have indicated that only a phenotypic subset of cancer cells, termed as the cancer stem cells (CSCs), is capable of initiating tumor growth and provide a reservoir of cells that cause tumor recurrence after therapy. Epithelial-mesenchymal transition (EMT), a cell type change from an epithelial cobblestone phenotype to an elongated fibroblastic phenotype, plays a critical role not only in tumor metastasis but also in tumor recurrence and contributes to drug resistance. Accumulating evidence has shown that cells with an EMT phenotype are rich sources for CSCs, suggesting a biological link between EMT and CSCs; thus study on the link will help understand the cellular and molecular mechanisms of tumor metastasis and drug resistance. CD29 is involved in EMT through cross-talk with cadherins and CD44 has been reported as a successful used marker for CSCs. Here, we try to address whether combination of CD29 and CD44 could be used to identify cancer stem-like cells undergoing EMT in squamous cell carcinoma (SCC) and compare the molecular differences between CD29high/CD44high and CD29low/CD44low cells in SCC. Expression pattern of CD29 and CD44 was analyzed in tissues of skin SCC and cultured A431 cells by immunostaining. Subtype cells of CD29high/CD44high and CD29low/CD44low A431 were sorted by fluorescence-activated cell sorting and proliferating abilities were assayed by cell counting, colony forming and tumorigenicity in NOD/SCID mice. Finally, to probe more deeply into the molecular differences between CD29high/CD44high and CD29low/CD44low A431 cells, gene microarray analysis was applied to compare gene expression profiling. Staining of CD29 and CD44 showed similar heterogeneous expression pattern with positive cells located in the invasion front of SCC tissue as well as in cultured A431 cells. Sorted CD29high/CD44high A431 cells had higher proliferating ability in vitro and in NOD/SCID mice as compared with CD29low/CD44low cells. Gene profiling identified differentiated gene expressions between CD29high/CD44high and CD29low/CD44low A431 cells. These genes are involved in cell cycle, cell malignant transformation, metastasis, drug resistance and EMT, implying that CD29high/CD44high cells have properties of CSCs and EMT. Our present results demonstrated heterogeneous gene expression patterns and different biological behavior in SCC. Combination of CD29 and CD44 can be used as markers to enrich CSCs in human SCC. Moreover, CD29high/CD44high cells exhibit molecular characteristics of EMT, suggesting that CSC-associated pathways were involved in EMT. Studies on correlation of CSCs and the cells undergoing EMT may explain some aspects of tumor progression and drug resistance.
越来越多的证据表明,只有癌症细胞的表型亚群,即癌症干细胞(CSCs),能够启动肿瘤生长,并为治疗后肿瘤复发提供细胞库。上皮-间充质转化(EMT),即细胞类型从鹅卵石状的上皮表型转变为拉长的成纤维细胞表型的改变,不仅在肿瘤转移中起关键作用,而且在肿瘤复发中起关键作用,并导致耐药性。越来越多的证据表明,具有 EMT 表型的细胞是 CSCs 的丰富来源,这表明 EMT 与 CSCs 之间存在生物学联系;因此,对这种联系的研究将有助于理解肿瘤转移和耐药性的细胞和分子机制。CD29 通过与钙粘蛋白的串扰参与 EMT,CD44 已被报道为 CSCs 的成功标记物。在这里,我们试图确定 CD29 和 CD44 的组合是否可用于鉴定鳞状细胞癌(SCC)中发生 EMT 的癌症样干细胞,并比较 SCC 中 CD29high/CD44high 和 CD29low/CD44low 细胞之间的分子差异。通过免疫染色分析皮肤 SCC 组织和培养的 A431 细胞中 CD29 和 CD44 的表达模式。通过荧光激活细胞分选对 CD29high/CD44high 和 CD29low/CD44low A431 的亚型细胞进行分选,并通过细胞计数、集落形成和 NOD/SCID 小鼠中的肿瘤形成来检测增殖能力。最后,为了更深入地探讨 CD29high/CD44high 和 CD29low/CD44low A431 细胞之间的分子差异,应用基因微阵列分析比较基因表达谱。CD29 和 CD44 的染色显示出与 SCC 组织中侵袭前沿以及培养的 A431 细胞中阳性细胞相似的异质性表达模式。与 CD29low/CD44low 细胞相比,分选的 CD29high/CD44high A431 细胞在体外和 NOD/SCID 小鼠中具有更高的增殖能力。基因谱分析确定了 CD29high/CD44high 和 CD29low/CD44low A431 细胞之间的分化基因表达。这些基因参与细胞周期、细胞恶性转化、转移、耐药性和 EMT,表明 CD29high/CD44high 细胞具有 CSCs 和 EMT 的特性。我们目前的结果表明 SCC 中存在异质基因表达模式和不同的生物学行为。CD29 和 CD44 的组合可用于富集人 SCC 中的 CSCs。此外,CD29high/CD44high 细胞表现出 EMT 的分子特征,表明与 CSC 相关的途径参与 EMT。对 CSCs 和 EMT 细胞之间相关性的研究可以解释肿瘤进展和耐药性的某些方面。
Signal Transduct Target Ther. 2025-8-5
Oncol Rev. 2024-7-18
Genes (Basel). 2023-6-16
Front Oncol. 2023-4-27
Nat Prod Rep. 2023-8-16
Front Oncol. 2022-6-17